These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 20201845)

  • 41. Selective dopamine D3 receptor antagonist YQA14 inhibits morphine-induced behavioral sensitization in wild type, but not in dopamine D3 receptor knockout mice.
    Lv Y; Hu RR; Jing M; Zhao TY; Wu N; Song R; Li J; Hu G
    Acta Pharmacol Sin; 2019 May; 40(5):583-588. PubMed ID: 30224637
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dopamine D1 and D3 receptor interactions in cocaine reward and seeking in rats.
    Galaj E; Harding W; Ranaldi R
    Psychopharmacology (Berl); 2016 Dec; 233(23-24):3881-3890. PubMed ID: 27582181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Blonanserin, an antipsychotic and dopamine D₂/D₃receptor antagonist, and ameliorated alcohol dependence.
    Takaki M; Ujike H
    Clin Neuropharmacol; 2013; 36(2):68-9. PubMed ID: 23503552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors.
    Weiss F; Ciccocioppo R; Parsons LH; Katner S; Liu X; Zorrilla EP; Valdez GR; Ben-Shahar O; Angeletti S; Richter RR
    Ann N Y Acad Sci; 2001 Jun; 937():1-26. PubMed ID: 11458532
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neurobiology of addiction. Toward the development of new therapies.
    Koob GF
    Ann N Y Acad Sci; 2000; 909():170-85. PubMed ID: 10911930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypothesis-driven medication discovery for the treatment of psychostimulant addiction.
    Xi ZX; Gardner EL
    Curr Drug Abuse Rev; 2008 Nov; 1(3):303-27. PubMed ID: 19430578
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Role of dopamine D3 receptors in the addictive properties of ethanol.
    Heidbreder CA; Andreoli M; Marcon C; Thanos PK; Ashby CR; Gardner EL
    Drugs Today (Barc); 2004 Apr; 40(4):355-65. PubMed ID: 15190388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats.
    Xi ZX; Newman AH; Gilbert JG; Pak AC; Peng XQ; Ashby CR; Gitajn L; Gardner EL
    Neuropsychopharmacology; 2006 Jul; 31(7):1393-405. PubMed ID: 16205781
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The psychology and neurobiology of addiction: an incentive-sensitization view.
    Robinson TE; Berridge KC
    Addiction; 2000 Aug; 95 Suppl 2():S91-117. PubMed ID: 11002906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.
    Pak AC; Ashby CR; Heidbreder CA; Pilla M; Gilbert J; Xi ZX; Gardner EL
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):585-602. PubMed ID: 16942635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
    Blum K; Gold MS
    Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference.
    Gyertyán I; Gál K
    Neuroreport; 2003 Jan; 14(1):93-8. PubMed ID: 12544838
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine D3 receptor antagonists in pathologic gambling.
    Bou Khalil R
    J Clin Psychopharmacol; 2013 Feb; 33(1):146-8. PubMed ID: 23288245
    [No Abstract]   [Full Text] [Related]  

  • 54. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications.
    Zaveri NT
    Curr Top Med Chem; 2011; 11(9):1151-6. PubMed ID: 21050175
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The selective dopamine D3 receptor antagonist, SR 21502, reduces cue-induced reinstatement of heroin seeking and heroin conditioned place preference in rats.
    Galaj E; Manuszak M; Babic S; Ananthan S; Ranaldi R
    Drug Alcohol Depend; 2015 Nov; 156():228-233. PubMed ID: 26429728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904.
    Banasikowski TJ; Beninger RJ
    Eur Neuropsychopharmacol; 2012 Oct; 22(10):761-8. PubMed ID: 22410316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting the dopamine D3 receptor: an overview of drug design strategies.
    Cortés A; Moreno E; Rodríguez-Ruiz M; Canela EI; Casadó V
    Expert Opin Drug Discov; 2016 Jul; 11(7):641-64. PubMed ID: 27135354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach.
    Mugnaini M; Iavarone L; Cavallini P; Griffante C; Oliosi B; Savoia C; Beaver J; Rabiner EA; Micheli F; Heidbreder C; Andorn A; Merlo Pich E; Bani M
    Neuropsychopharmacology; 2013 Jan; 38(2):302-12. PubMed ID: 22968817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A.
    Di Ciano P; Underwood RJ; Hagan JJ; Everitt BJ
    Neuropsychopharmacology; 2003 Feb; 28(2):329-38. PubMed ID: 12589386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats.
    Gál K; Gyertyán I
    Drug Alcohol Depend; 2006 Jan; 81(1):63-70. PubMed ID: 16005579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.